MiNK Therapeutics presented new translational data from its ongoing Phase 2 study of agenT-797 at the American Association for Cancer Research (AACR) IO Annual Meeting on February 24, 2025. The study evaluates agenT-797 in combination with botensilimab and balstilimab (BOT/BAL) in patients with refractory gastroesophageal cancer.
The data demonstrated a powerful synergy between MiNK’s allo-iNKT cells, checkpoint inhibitors, and approved chemotherapy, leading to robust immune reactivation and clinical activity in unresponsive tumors. Dr. Jennifer Buell, President and CEO, highlighted the potential for durable clinical benefits by intensifying immunologic activity and reinvigorating memory T cells.
These findings underscore the unique position of iNKT cells in the cell therapy space, with the potential to transform both access and efficacy for patients. The combination aims to drive anti-tumor immune cells into the tumor microenvironment, offering a promising approach for difficult-to-treat cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.